Pulmatrix Inc. Common Stock (PULM)

About PULM

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in develo…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

2

Website

www.pulmatrix.com

Fundamentals

1-day range

$1.5$1.57

Market cap

$6.35M

P/E (trailing)

—

P/E (forward)

-0.34

EPS (trailing)

$-1.10

Dividend yield

—

Beta

—

Avg. volume

48.5K

Dividend pay date

February 6, 2019

Pulmatrix Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PULM

  Pulmatrix Inc. Common Stock

  $1.51

  ▼ 0.66%
  Market cap $6.35MP/E —
  $1.16$5.5
• ALZN

  Alzamend Neuro Inc. Common Stock

  $1.66

  ▼ 0.30%
  Market cap $6.42MP/E —
  $0.84$2.68
• ACXP

  Acurx Pharmaceuticals Inc. Common Stock

  $1.45

  ▼ 1.03%
  Market cap $6.15MP/E —
  $1.31$8.34
• HCWB

  HCW Biologics Inc. Common Stock

  $3.39

  ▲ 6.94%
  Market cap $6.06MP/E —
  $1.5$38.16
• JUNS

  Jupiter Neurosciences Inc. Common Stock

  $4.59

  ▼ 6.13%
  Market cap $5.65MP/E —
  $4.1$138
• PCSA

  Processa Pharmaceuticals Inc. Common Stock

  $2.07

  ▼ 1.90%
  Market cap $7.09MP/E —
  $1.67$14.24
• NCNA

  NuCana plc American Depositary Share

  $1.79

  ▲ 21.43%
  Market cap $5.62MP/E 0.01
  $1.21$7.22

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
  Benzinga · 8/13/2026

Institutional Ownership

March 31, 2026

Total shares held

314.8K

Total value held

$406.1K

Institutional holders

14